639 related articles for article (PubMed ID: 22364685)
1. Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial.
Corbacioglu S; Cesaro S; Faraci M; Valteau-Couanet D; Gruhn B; Rovelli A; Boelens JJ; Hewitt A; Schrum J; Schulz AS; Müller I; Stein J; Wynn R; Greil J; Sykora KW; Matthes-Martin S; Führer M; O'Meara A; Toporski J; Sedlacek P; Schlegel PG; Ehlert K; Fasth A; Winiarski J; Arvidson J; Mauz-Körholz C; Ozsahin H; Schrauder A; Bader P; Massaro J; D'Agostino R; Hoyle M; Iacobelli M; Debatin KM; Peters C; Dini G
Lancet; 2012 Apr; 379(9823):1301-9. PubMed ID: 22364685
[TBL] [Abstract][Full Text] [Related]
2. Defibrotide in the prevention and treatment of veno-occlusive disease in autologous and allogeneic stem cell transplantation in children.
Qureshi A; Marshall L; Lancaster D
Pediatr Blood Cancer; 2008 Apr; 50(4):831-2. PubMed ID: 18286502
[TBL] [Abstract][Full Text] [Related]
3. Defibrotide plus best standard of care compared with best standard of care alone for the prevention of sinusoidal obstruction syndrome (HARMONY): a randomised, multicentre, phase 3 trial.
Grupp SA; Corbacioglu S; Kang HJ; Teshima T; Khaw SL; Locatelli F; Maertens J; Stelljes M; Stepensky P; Lopez P; Amber V; Pagliuca A; Richardson PG; Mohty M
Lancet Haematol; 2023 May; 10(5):e333-e345. PubMed ID: 37001534
[TBL] [Abstract][Full Text] [Related]
4. BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation.
Dignan FL; Wynn RF; Hadzic N; Karani J; Quaglia A; Pagliuca A; Veys P; Potter MN; ;
Br J Haematol; 2013 Nov; 163(4):444-57. PubMed ID: 24102514
[TBL] [Abstract][Full Text] [Related]
5. Hepatic veno-occlusive disease in pediatric stem cell transplantation: impact of pre-emptive antithrombin III replacement and combined antithrombin III/defibrotide therapy.
Haussmann U; Fischer J; Eber S; Scherer F; Seger R; Gungor T
Haematologica; 2006 Jun; 91(6):795-800. PubMed ID: 16769582
[TBL] [Abstract][Full Text] [Related]
6. Defibrotide for Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome: Interim Results from a Treatment IND Study.
Richardson PG; Smith AR; Triplett BM; Kernan NA; Grupp SA; Antin JH; Lehmann L; Shore T; Iacobelli M; Miloslavsky M; Hume R; Hannah AL; Nejadnik B; Soiffer RJ;
Biol Blood Marrow Transplant; 2017 Jun; 23(6):997-1004. PubMed ID: 28285079
[TBL] [Abstract][Full Text] [Related]
7. Defibrotide for children and adults with hepatic veno-occlusive disease post hematopoietic cell transplantation.
Corbacioglu S; Richardson PG
Expert Rev Gastroenterol Hepatol; 2017 Oct; 11(10):885-898. PubMed ID: 28825848
[TBL] [Abstract][Full Text] [Related]
8. Prevention of veno-occlusive disease with defibrotide after allogeneic stem cell transplantation.
Chalandon Y; Roosnek E; Mermillod B; Newton A; Ozsahin H; Wacker P; Helg C; Chapuis B
Biol Blood Marrow Transplant; 2004 May; 10(5):347-54. PubMed ID: 15111934
[TBL] [Abstract][Full Text] [Related]
9. Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure.
Richardson PG; Riches ML; Kernan NA; Brochstein JA; Mineishi S; Termuhlen AM; Arai S; Grupp SA; Guinan EC; Martin PL; Steinbach G; Krishnan A; Nemecek ER; Giralt S; Rodriguez T; Duerst R; Doyle J; Antin JH; Smith A; Lehmann L; Champlin R; Gillio A; Bajwa R; D'Agostino RB; Massaro J; Warren D; Miloslavsky M; Hume RL; Iacobelli M; Nejadnik B; Hannah AL; Soiffer RJ
Blood; 2016 Mar; 127(13):1656-65. PubMed ID: 26825712
[TBL] [Abstract][Full Text] [Related]
10. The use of defibrotide in blood and marrow transplantation.
Richardson PG; Carreras E; Iacobelli M; Nejadnik B
Blood Adv; 2018 Jun; 2(12):1495-1509. PubMed ID: 29945939
[TBL] [Abstract][Full Text] [Related]
11. Safety and effects of prophylactic defibrotide for sinusoidal obstruction syndrome in hematopoietic stem cell transplantation.
Park M; Park HJ; Eom HS; Kwon YJ; Park JA; Lim YJ; Yoon JH; Kong SY; Ghim TT; Lee HW; Yun T; Park BK
Ann Transplant; 2013 Jan; 18():36-42. PubMed ID: 23792499
[TBL] [Abstract][Full Text] [Related]
12. Interventions for prophylaxis of hepatic veno-occlusive disease in people undergoing haematopoietic stem cell transplantation.
Cheuk DK; Chiang AK; Ha SY; Chan GC
Cochrane Database Syst Rev; 2015 May; 2015(5):CD009311. PubMed ID: 26017019
[TBL] [Abstract][Full Text] [Related]
13. Defibrotide for the management of sinusoidal obstruction syndrome in patients who undergo haemopoietic stem cell transplantation.
Coutsouvelis J; Avery S; Dooley M; Kirkpatrick C; Spencer A
Cancer Treat Rev; 2016 Nov; 50():200-204. PubMed ID: 27721142
[TBL] [Abstract][Full Text] [Related]
14. Defibrotide for the treatment of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation.
Corbacioglu S; Kernan N; Lehmann L; Brochstein J; Revta C; Grupp S; Martin P; Richardson PG
Expert Rev Hematol; 2012 Jun; 5(3):291-302. PubMed ID: 22780209
[TBL] [Abstract][Full Text] [Related]
15. Prophylactic defibrotide in allogeneic stem cell transplantation: minimal morbidity and zero mortality from veno-occlusive disease.
Dignan F; Gujral D; Ethell M; Evans S; Treleaven J; Morgan G; Potter M
Bone Marrow Transplant; 2007 Jul; 40(1):79-82. PubMed ID: 17502897
[TBL] [Abstract][Full Text] [Related]
16. Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial.
Richardson PG; Soiffer RJ; Antin JH; Uno H; Jin Z; Kurtzberg J; Martin PL; Steinbach G; Murray KF; Vogelsang GB; Chen AR; Krishnan A; Kernan NA; Avigan DE; Spitzer TR; Shulman HM; Di Salvo DN; Revta C; Warren D; Momtaz P; Bradwin G; Wei LJ; Iacobelli M; McDonald GB; Guinan EC
Biol Blood Marrow Transplant; 2010 Jul; 16(7):1005-17. PubMed ID: 20167278
[TBL] [Abstract][Full Text] [Related]
17. Defibrotide sodium for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome.
Richardson PG; Triplett BM; Ho VT; Chao N; Dignan FL; Maglio M; Mohty M
Expert Rev Clin Pharmacol; 2018 Feb; 11(2):113-124. PubMed ID: 29301447
[TBL] [Abstract][Full Text] [Related]
18. Defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome following nontransplant-associated chemotherapy: Final results from a post hoc analysis of data from an expanded-access program.
Kernan NA; Richardson PG; Smith AR; Triplett BM; Antin JH; Lehmann L; Messinger Y; Liang W; Hume R; Tappe W; Soiffer RJ; Grupp SA
Pediatr Blood Cancer; 2018 Oct; 65(10):e27269. PubMed ID: 29873895
[TBL] [Abstract][Full Text] [Related]
19. Defibrotide: a review of its use in severe hepatic veno-occlusive disease following haematopoietic stem cell transplantation.
Keating GM
Clin Drug Investig; 2014 Dec; 34(12):895-904. PubMed ID: 25351934
[TBL] [Abstract][Full Text] [Related]
20. Late-onset hepatic veno-occlusive disease post autologous peripheral stem cell transplantation successfully treated with oral defibrotide.
Shah MS; Jeevangi NK; Joshi A; Khattry N
J Cancer Res Ther; 2009; 5(4):312-4. PubMed ID: 20160371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]